MPN

Reintroducing treatment with Jakafi in patients with myelofibrosis after previous discontinuation extended overall survival compared to those patients who stopped permanently, although there was a substantial rate of permanent treatment discontinuation with this therapy.

At four-year follow up, treatment with givinostat, a histone-deacetylase inhibitor, continued to be safe and effective with no serious or life-threatening side effects.

Of note, estimates show that there are more than 25,000 patients undergoing allogeneic hematopoietic cell transplantations throughout the United States and beyond. Recent study results show that these patients may be at a higher risk for de novo atrial fibrillation.

Watch our Myeloproliferative Neoplasms Webinar where an expert panel discussed topics highly relevant to patients, caregivers and advocates right now.

In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.

Watch the entire MPN Heroes program here!

Patients with myeloproliferative neoplasm (MPN) may benefit from this combination treatment if they are in the accelerated or blast phase of the disease.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Ruben Mesa about understanding a myeloproliferative neoplasm diagnosis.

Individuals living with myeloproliferative neoplasm (MPN) often face a markedly different experience compared to those patients with other types of blood cancer. Unfortunately, there tends to be less known about this population due to its smaller size. But tools like the recently published “Blood Cancer in America” 2020 survey aim to help highlight the disparities faced by the MPN community and give a voice to those who may feel unheard.

MPN Hero Dr. Irum Khan discusses how education events for patients with cancer are helpful to both the patient and the clinician.

Jeffrey Glen Jones – an American illustrator who started doing comic books about 25 years ago – is using his creative talents to illustrate the stories of those impacted by MPNs, as part of a campaign called Rare Reflections: MPNs Unmasked.

In the 2020 Hematology 1 special edition of CURE magazine, we highlight what it means to be an everyday hero by living with MPN or helping patients with the disease cope with it.

The expert who created an assessment tool to help patients with myeloproliferative neoplasms explain their symptoms to their care ream shares how the idea came to fruition.

Kurt Schroeder, a research nurse, pushes for a patient-first mentality, especially as they participate in a clinical trial.

Ann McMullin fought for her son to be properly diagnosed and is advocating for more education among medical professionals of rare diseases like her son’s essential thrombocythemia.

As a guest speaker at the 2019 MPN Heroes ® Recognition Ceremony, Dr. David C. Fajenbaum had the chance to discuss how translational research is a vital part of getting the right treatment to patients with cancer.

Emergency room visits are costly and take a lot of time patients with cancer don’t have, which is why the creation of a 24-hour clinic to address cancer related symptoms and treatment side effects could prove vital for patients.

Cannon McMullin was diagnosed with essential thrombocythemia at 8 years old and has remained positive through years of treatment by focusing on the things he likes to do.

For Natalie Catalano, caregiving for her daughter with essential thrombocythemia included not only being a rock of support, but also being a vocal advocate for her daughter’s care team to make the right diagnosis.

Madeleine Henriquez noticed that the mental health care of patients with MPN was being overlooked and took action in a way that has changed her community for the better.

Patients with rare blood cancers are not all the same, and this understanding has helped Dr. Irum Khan become an advocate for people with these conditions — and an MPN Hero.

At the 2019 MPN Heroes® event Tammy Matuska, B.S.N., RN, known as the "lifeline to patients," was honored for her outstanding work for patients with MPN.

At the annual MPN Heroes event, Dr. David Fajgenbaum, who discovered a treatment for his own rare disorder, shared insights on turning hope into action when faced with adversity.

Here is a list of the recent trial initiations that occurred within the myeloproliferative neoplasm cancer space.